CJC-1295 vs ipamorelin: a side-by-side comparison.

CJC-1295 vs ipamorelin is one of the most common peptide-research framings. But the "versus" framing misses the point. They aren't competing on the same receptor or for the same job. They're different tools that produce different signals.

This comparison is structured around the experimental question you're actually asking.

If you want to study the GHRH receptor in isolation, CJC-1295 alone is the cleaner tool. If you want to study the ghrelin receptor in isolation, ipamorelin alone is the cleaner tool. If you want to study how the two receptors interact when both are activated, the combination is the right setup.

If you want body-composition outcomes in healthy adults? The published evidence base supports none of these uses. That's a separate problem the "versus" framing doesn't resolve.

The side-by-side comparison

Here's how they line up across the dimensions that actually matter. These are drawn from the published literature on both molecules and the receptor-pharmacology reviews cited at the end.

Mechanism: two different doors into the same room

The fundamental difference is the receptor each peptide hits.

The GHRH receptor is the canonical target. It's where the brain's growth hormone-releasing hormone normally lands. When CJC-1295 binds it on pituitary GH-producing cells (called somatotrophs), the signal travels through a Gs-protein, then adenylyl cyclase, then cyclic AMP, then protein kinase A. That's the textbook GHRH cascade.

The ghrelin receptor (GHS-R1a) sits on the same cells. When ipamorelin binds it, the signal goes through a different chain: Gq-protein, then phospholipase C, then IP3, then calcium release.

The two cascades end up at the same place — GH release into the bloodstream — but they get there through independent routes.

That's the mechanistic basis for the synergy when you stack them. Activating both cascades at once produces a GH pulse larger than the sum of the individual pulses. In clinical-pharmacology studies, combined-stack pulse amplitudes typically run 3 to 5 times larger than either peptide alone.

Whether that bigger pulse translates to better tissue outcomes is the empirical question controlled trials would need to answer. None have been done.

CJC-1295 (no DAC)

GHRH analog 29 aa No DAC

The GHRH-receptor agonist cited across the receptor-pharmacology and synergy studies in this comparison. Lab-verified identity and purity.

View CJC-1295

Half-life: where the "DAC" question matters

CJC-1295 actually comes in two forms. They're so different in how they behave that you should think of them as two drugs.

The "no DAC" form (also called Modified GRF 1-29) has a half-life of about 30 minutes. That's a modest extension over native GHRH's 7 minutes, achieved through four amino-acid substitutions that resist enzyme degradation. It produces a discrete GH pulse that decays within a few hours. That mimics natural pulsatility.

The "DAC" form (Drug Affinity Complex) covalently glues itself to a blood-plasma protein called albumin. That extends half-life to 6 to 8 days. It produces continuous receptor activation for days, smoothing out the pulsatile pattern.

That second form is more convenient to dose. It's also less physiological. Pituitary cells evolved to respond to pulses, not constant signal.

Ipamorelin's half-life is about 2 hours. That's intermediate. It's long enough to keep a sustained ghrelin-receptor signal going during the GHRH-receptor pulse from co-administered CJC-1295 no DAC. That's why the no-DAC variant is the standard stacking partner. The DAC variant's much longer half-life creates a temporal mismatch with ipamorelin's shorter window.

The practical upshot for experimental design. The no-DAC variant's shorter half-life necessitates more frequent administration intervals in studies examining pulsatile GH dynamics. The DAC variant's extended half-life makes it better suited to designs examining sustained receptor engagement, though at the cost of physiological pulsatility. The half-life mismatch with ipamorelin is a relevant variable in any co-administration study design.

Side effects: where they differ

The most consequential side-effect difference between these two peptides is what neither of them does.

Older GHRPs like GHRP-6 and hexarelin produce notable jumps in cortisol and prolactin alongside the GH release. Cortisol antagonizes GH's anabolic effects. Prolactin has its own metabolic actions. The extra hormonal noise complicates any clean GH-axis experiment.

Ipamorelin is the cleanest GHRP in this respect. Clinical-pharmacology studies showed it produces minimal cortisol, prolactin, or ACTH elevation at GH-stimulating doses. That's the defining attribute that separates it from older ghrelin-receptor agonists.

CJC-1295 doesn't engage the cortisol or prolactin pathways at all. It hits the GHRH receptor, not the ghrelin receptor. So you get a clean GHRH signal with no expected collateral hormone effects.

Where CJC-1295 does carry risk is the standard GH-axis package: edema, joint stiffness, paresthesias (tingling), and insulin resistance. Any agent that meaningfully raises GH and IGF-1 carries these.

The shared concerns: sustained IGF-1 elevation carries theoretical cancer risks. GH antagonizes insulin, so chronic stimulation can worsen glucose control. Receptor downregulation (tachyphylaxis) is a theoretical worry over long-term dosing for both.

The Phase III readouts: one failed, one never tried

The most important real-world data point in either molecule's file is the failed Phase III ipamorelin trial for postoperative ileus.

Novo Nordisk advanced ipamorelin into Phase III on the rationale that ghrelin-receptor activation would stimulate gut motility after surgery. The trial failed its primary endpoint. Clinical development was discontinued. Ipamorelin was shelved as a therapeutic candidate.

CJC-1295 never reached an analogous Phase III readout. Its development as a once-weekly GHRH-replacement therapy (the DAC form) was halted after a fatal adverse event in an unrelated CJC-1131 trial led to broader scrutiny of the platform. The program wasn't revived. The molecule effectively transitioned to research-supply distribution without ever clearing a Phase III hurdle on any indication.

Why they're stacked rather than chosen between

The "CJC-1295 vs ipamorelin" framing is built into search queries and forum titles. The underlying pharmacology doesn't support it. The two molecules bind different receptors. They produce different signals. They're complementary, not competing.

The choice researchers actually make — when they make one rather than stacking — depends on the experimental question:

• CJC-1295 alone is right when the question is specifically about GHRH-receptor pharmacology, pulsatile GH dynamics, or IGF-1 production downstream of GHRH stimulation in isolation.
• Ipamorelin alone is right when the question is specifically about ghrelin-receptor pharmacology, the cleanest GHRP-class effects without cortisol/prolactin confounders, or peripheral ghrelin-receptor effects (pain models, cachexia models).
• The combination is right when the question is specifically about receptor synergy, supra-additive GH pulse dynamics, or the combined effect of GHRH-R and ghrelin-R co-stimulation.

In the popular literature and grey-market context, the stacked combination is far more commonly discussed than either compound alone. The marketing logic favors "two peptides for synergy" over "one peptide for clarity." That preference reflects how the products are promoted, not a pharmacological necessity — and it is not a pattern endorsed by controlled clinical evidence.

CJC-1295 (no DAC)

10 mg ≥99% pure Lyophilized

Modified GRF 1-29 · 29-aa GHRH analog. The same reference compound used across the cited preclinical studies. COA available with each lot.

Learn more

Regulatory status: identical where it matters

From a regulatory standpoint, CJC-1295 and ipamorelin sit in essentially the same place in 2026.

Neither is FDA-approved for any indication. Both have been placed on FDA bulks-not-eligible-for-503A-compounding lists, which restricts legal clinical access through compounding pharmacies. Both are on the WADA Prohibited List under category S2. Both are reliably detectable at WADA-accredited labs using validated LC-MS/MS methods at sub-ng/mL urine concentrations.

The volume of detection-methodology literature is itself meaningful. Four major detection-methods papers on these peptides have been published since 2021. That tells you regulatory bodies have taken misuse seriously enough to fund the analytical chemistry needed to catch them.

Major sports leagues prohibit both. Published detection-methodology studies have demonstrated reliable identification of both peptides in urine and blood matrices at sub-ng/mL concentrations using validated LC-MS/MS methods.